Publication:
The Ubiquitin Proteasome System in Neuromuscular Disorders: Moving Beyond Movement.

dc.contributor.authorBachiller, Sara
dc.contributor.authorAlonso-Bellido, Isabel M
dc.contributor.authorReal, Luis Miguel
dc.contributor.authorPérez-Villegas, Eva María
dc.contributor.authorVenero, José Luis
dc.contributor.authorDeierborg, Tomas
dc.contributor.authorArmengol, José Ángel
dc.contributor.authorRuiz, Rocío
dc.date.accessioned2024-10-23T13:07:18Z
dc.date.available2024-10-23T13:07:18Z
dc.date.issued2020-09-03
dc.description.abstractNeuromuscular disorders (NMDs) affect 1 in 3000 people worldwide. There are more than 150 different types of NMDs, where the common feature is the loss of muscle strength. These disorders are classified according to their neuroanatomical location, as motor neuron diseases, peripheral nerve diseases, neuromuscular junction diseases, and muscle diseases. Over the years, numerous studies have pointed to protein homeostasis as a crucial factor in the development of these fatal diseases. The ubiquitin-proteasome system (UPS) plays a fundamental role in maintaining protein homeostasis, being involved in protein degradation, among other cellular functions. Through a cascade of enzymatic reactions, proteins are ubiquitinated, tagged, and translocated to the proteasome to be degraded. Within the ubiquitin system, we can find three main groups of enzymes: E1 (ubiquitin-activating enzymes), E2 (ubiquitin-conjugating enzymes), and E3 (ubiquitin-protein ligases). Only the ubiquitinated proteins with specific chain linkages (such as K48) will be degraded by the UPS. In this review, we describe the relevance of this system in NMDs, summarizing the UPS proteins that have been involved in pathological conditions and neuromuscular disorders, such as Spinal Muscular Atrophy (SMA), Charcot-Marie-Tooth disease (CMT), or Duchenne Muscular Dystrophy (DMD), among others. A better knowledge of the processes involved in the maintenance of proteostasis may pave the way for future progress in neuromuscular disorder studies and treatments.
dc.format.number17es_ES
dc.format.volume21es_ES
dc.identifier.doi10.3390/ijms21176429
dc.identifier.e-issn1422-0067es_ES
dc.identifier.journalInternational journal of molecular scienceses_ES
dc.identifier.otherhttp://hdl.handle.net/10668/16230
dc.identifier.pubmedID32899400es_ES
dc.identifier.urihttps://hdl.handle.net/20.500.12105/25258
dc.language.isoeng
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectUPS
dc.subjectNeuromuscular disorder
dc.subjectNeuromuscular junction
dc.subjectProteasome
dc.subjectSynapse
dc.subjectUbiquitin
dc.subject.meshAnimals
dc.subject.meshHumans
dc.subject.meshNeuromuscular Diseases
dc.subject.meshProteasome Endopeptidase Complex
dc.subject.meshUbiquitin
dc.subject.meshUbiquitin-Protein Ligase Complexes
dc.subject.meshUbiquitination
dc.titleThe Ubiquitin Proteasome System in Neuromuscular Disorders: Moving Beyond Movement.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files